Literature DB >> 18572127

Effectiveness of CT-guided percutaneous biopsies of the spine: an analysis of 202 examinations.

Christoph M Heyer1, Abdulgani Al-Hadari, Klaus-Michael Mueller, Axel Stachon, Volkmar Nicolas.   

Abstract

RATIONALE AND
OBJECTIVES: The study goal was to retrospectively evaluate the effectiveness of computed tomography (CT)-guided spinal biopsies.
MATERIAL AND METHODS: Two hundred two CT-guided vertebral biopsies performed between May 1999 and June 2004 in 187 patients were retrospectively analyzed. Patient characteristics (age, sex, antibiotic therapy), technical parameters (depth and number of biopsies, needle approach), lesion features (spinal level, osteolysis, fluid collections, soft tissue tumor), and complications were documented. Furthermore, histopathological and microbiological diagnoses were considered.
RESULTS: There were two focal hematomas in our study group (complication rate: 1%). Histopathological diagnosis was established in 74% of examinations with spondylitis (41% of cases) being most common. In spinal tumors (27% of cases), malignant lesions were found in 52 of 54 examinations (96%). Osteolysis was diagnosed in 98% of patients with spondylitis and in 87% of patients with tumors (P < .01). Spinal tumors were most commonly seen in the sacrum (53%, P < .001), whereas spondylitis typically occurred in the lumbar spine (55%, P = .001). Neither patient age nor sex, needle approach, needle depth, or vertebral abnormalities showed a significant impact on diagnostic accuracy. Microbiological tests were performed in 98 patients (49%); 62 of 98 patients (65%) received antibiotic therapy. In 12 of 62 patients (19%) with antibiotic therapy and in 9 of 36 patients (25%) without antibiotic treatment, microbiological tests were positive (P = .153). Staphylococcus aureus was found in 9 of 21 examinations (43%).
CONCLUSIONS: CT-guided vertebral biopsy is a safe and effective procedure to establish final diagnosis in spinal lesions of unclear origin. Patient characteristics, lesions features, and technical considerations did not influence sample quality. In spondylitis, which was commonly caused by Staphylococcus aureus, microbiological yield was low regardless of antibiotic therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18572127     DOI: 10.1016/j.acra.2008.01.020

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  6 in total

1.  Rosai-Dorfman disease with spinal cord compression: a diagnostic challenge.

Authors:  Sara Sciacca; Kostantinos Barkas; Lauren Heptinstall; Christopher McNamara; Rohit Shetty
Journal:  Eur Spine J       Date:  2014-11-15       Impact factor: 3.134

Review 2.  Review article: the current status of CT-guided needle biopsy of the spine.

Authors:  Asif Saifuddin; Valentina Palloni; Hannah du Preez; Syed Ehtasham Junaid
Journal:  Skeletal Radiol       Date:  2020-08-19       Impact factor: 2.199

3.  CT-guided fine-needle aspiration in vertebral osteomyelitis: true usefulness of a common practice.

Authors:  Enrique Marco de Lucas; Andrés González Mandly; Agustín Gutiérrez; Raúl Pellón; Laura Martín-Cuesta; Javier Izquierdo; Elena Sánchez; Eva Ruiz; Fernando Quintana
Journal:  Clin Rheumatol       Date:  2008-11-29       Impact factor: 2.980

4.  [Benign and semimalignant spinal tumors. Characteristics in children and adults].

Authors:  V Bullmann; U Liljenqvist
Journal:  Orthopade       Date:  2013-09       Impact factor: 1.087

5.  Vertebral Fractures of Unknown Origin: Role of Computed Tomography-Guided Biopsy.

Authors:  Paolo Spinnato; Alberto Bazzocchi; Giancarlo Facchini; Giacomo Filonzi; Cristina Nanni; Ilaria Rambaldi; Eugenio Rimondi; Stefano Fanti; Ugo Albisinni
Journal:  Int J Spine Surg       Date:  2018-12-21

6.  A fatal case of spinal tuberculosis mistaken for metastatic lung cancer: recalling ancient Pott's disease.

Authors:  Felix C Ringshausen; Andrea Tannapfel; Volkmar Nicolas; Andreas Weber; Hans-Werner Duchna; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-11-20       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.